KSQ Therapeutics
Precision oncology company using CRISPR-based functional genomics platform to identify and validate novel drug targets and develop best-in-class therapies for cancer patients.
Website
https://www.ksqtx.comLocation
Cambridge, Massachusetts, USA
Founded
2015
Investors
1
Categories
biotech, oncology, precision-medicine, crispr, functional-genomics
Notes
KSQ Therapeutics is a precision oncology company leveraging its proprietary CRISPR-based functional genomics platform, CRISPRomics, to systematically discover and validate novel drug targets in cancer. The company's approach enables genome-wide, unbiased discovery of targets across multiple tumor types and patient populations.
KSQ's platform interrogates the entire genome in cancer models to identify genes essential for tumor survival, then develops targeted therapies against the most promising and validated targets.
Team
- Deborah Dunsire, M.D. - President & Chief Executive Officer (former CEO of XTuit Pharmaceuticals, Millennium Pharmaceuticals)
- LinkedIn: linkedin.com/in/deborah-dunsire
- Adam Bass, M.D. - Chief Scientific Officer
- Richard Chesworth, Ph.D. - Chief Technology Officer
- Claire Mazumdar - Chief Financial Officer
Additional Research Findings
- Founded in 2015
- Headquarters in Cambridge, Massachusetts
- Proprietary CRISPRomics platform for target discovery
- Pipeline includes programs targeting USP1, Werner Helicase, and other novel targets
- Uses functional genomics to identify synthetic lethalities in cancer
- Backed by investors including Polaris Partners, Third Rock Ventures, and Pfizer Ventures
- Raised over $200M in funding
Sources
Investors
| Name | Location | Type | Stages | Portfolio |
|---|---|---|---|---|
| Polaris Partners | US | biotech-focused | - | 33 |